Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2026-03-03 @ 8:11 AM
Study NCT ID:
NCT01646034
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2022-10-12
First Post:
2012-06-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
Sponsor:
The Netherlands Cancer Institute
Organization:
Study Overview
Official Title:
High-dose Alkylating Chemotherapy in Oligo-metastatic Breast Cancer Harboring Homologous Recombination Deficiency
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Oligo
Brief Summary:
This study investigates the effect of high-dose alkylating chemotherapy compared with standard chemotherapy as part of a multimodality treatment approach in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2012-000838-19 | EUDRACT_NUMBER | None | View |